Alemtuzumab reduces disability in patients with MS
It was found that patients given alemtuzumab were almost twice to achieve an improvement in physical disabilities compared with those given interferon beta-1a. It is a drug used to treat multiple sclerosis (MS) can reverse some of the physical disabilities created by the neurological disease, according to new research.
In the two-year study, people with relapsing-remitting MS who did not adequately respond to at least one other MS drug were treated with either alemtuzumab or interferon beta-1a. The results show that those given alemtuzumab were more likely to see improvements in pre-existing disabilities.
“This is big news for patients with MS,” says lead researcher Gavin Giovannoni, professor of neurology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London. “In the first one or two years, a third of patients [taking alemtuzumab] not only stabilised but saw improvements in their disability. Moreover that seems to goes up beyond two years to 40% of patients.”
The researchers found nearly 28% of patients in the alemtuzumab group had improved their disability score by at least 1 point at the end of the trial, with scores ranging from 0 to 10. They also found that disability scores improved in 15% of patients given interferon.